Simple Summary Immunotherapy has demonstrated the ability to reduce the risk of
recurrence for melanoma following surgical resection and improve survival in patients with …

Melanoma treatment has been revolutionized over the past decade. Long-term results with
immuno-oncology (IO) agents and targeted therapies are providing evidence of durable …

PURPOSE Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–
blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in …

PURPOSE Limited prospective data are available on sequential immunotherapy and
BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. METHODS SECOMBIT is …

Background Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-
free and overall survival than ipilimumab alone in a trial involving patients with advanced …

PURPOSE Outcome measures that comprehensively capture attributes of immuno-oncology
agents, including prolonged treatment-free time and persistent treatment-related adverse …

BRAF-V600 mutations occur in approximately 50% of patients with metastatic melanoma.
Immune-checkpoint inhibitors and targeted therapies are both active as first-line treatments …

Aim: To compare effectiveness of nivolumab+ ipilimumab (NIVO+ IPI) versus BRAF+ MEK
inhibitors (BRAFi+ MEKi) in patients with BRAF-mutant advanced melanoma in the real …

Abstract Purpose of Review The treatment strategy for BRAF-mutated melanoma remains
unsatisfactory, although the advent of immune checkpoint inhibition has improved the …

Background The disutilities of adverse events (AEs) are important inputs for cost-utility
analysis (CUA), reflecting the impacts of AEs on health outcomes. Health technology …